cancer-detection
(3)
Shlomi Madar
Shlomi Madar is the CEO of SpotitEarly, an Englewood, New Jersey biotech developing a non-invasive, breath-based multi-cancer screening test that pairs trained scent-detection dogs with a deep-learning platform. He holds a PhD in cancer research from the Weizmann Institute of Science and has spent more than fifteen years in life sciences and healthcare, previously serving as VP of Strategic Alliances at OncoHost and working on the Weizmann Institute's innovation arm. In May 2025 SpotitEarly closed a $20.3M Series A behind clinical results the company reports at roughly 94% sensitivity and specificity across four cancer types.
Craig Davis
Craig Davis is the President and CEO of NovaScan, a Chicago-based clinical-stage oncology company building a low-cost, point-of-care platform that uses bioimpedance and machine learning to detect and stratify cancer in real time. A medtech executive and investor with more than two decades of experience, he has raised over $20 million for NovaScan, secured a CPRIT grant, and helped steer clinical trials in skin, lung, breast, GI and pancreatic cancers. Earlier in his career he helped shape companies including New Aera (acquired by Inogen), Merge Healthcare (IPO; later acquired by IBM), and OrthoScan, and was a partner at healthcare investment bank Healthios.
Gene Dolgoff
Gene Dolgoff is the founder, CEO, CTO, and Chairman of Holobeam Technologies, a Long Island biotech building holographic tools to detect and treat cancer. He has been making holograms since 1964, holds over 65 patents worldwide, built the world's first LCD projector, and consulted with Gene Roddenberry on the concept that became the Star Trek Holodeck. Today his company is developing Holographic Energy Teleportation (HET), advanced nanoparticles, and a new class of MRI imaging - aiming, in his words, to teleport energy through the body to kill cancer cells.